SMAD2 and neoplasm: Based on our data, 66.40% (81 cases) of tumours had high expression of Smad2 followed by positive TGF-β signalling (described above and 33.60% (41 cases) of tumours represented a low expression of Smad2 with negative TGF-β signalling through cytoplasmic staining.